MHRC Talk: Achieving Robust IP Protection of AI/ML Digital Health and Precision Medicine Innovation

Enjoy free admission, all are welcome.

* Seats are limited and will be allocated on a 'first in, first served' basis.
* Online link will be provided if the seats are full.
* Please note that NO Physiotherapy (PT) and Occupational Therapy (OT) CPD points will be offered by the talk.

Topic:

Achieving Robust IP Protection of AI/ML Digital Health and Precision Medicine Innovation

Speaker:

Mr Roger Kuan
Partner
US Head of Digital Health and Precision Medicine Practice
Norton Rose Fulbright US LLP

Abstract:

The rapid convergence of digital technologies, particularly AI and ML, with healthcare and life sciences has fundamentally reshaped healthcare delivery, accelerating significantly over the past five years. This evolution marks a shift from traditional medicine to a personalized, data-driven model. However, protecting intellectual property (IP) in digital health remains challenging in the U.S. due to ongoing uncertainty under Section 101 regarding patent eligibility for AI and ML-based innovations.

This presentation will outline strategic approaches for developing a resilient IP portfolio that can withstand Section 101 scrutiny. It will include practical guidance on identifying and framing invention-worthy contributions in this dynamic sector. Additionally, a case study will illustrate how robust IP protection directly enhanced the commercial success of a digital health solution, emphasizing the crucial role data rights play in maximizing long-term commercial value.

Biography:

Roger leads the U.S. Digital Health and Precision Medicine Practice at Norton Rose Fulbright, advising digital health companies and research institutions on intellectual property (IP), data rights, and regulatory compliance.

His expertise covers comprehensive IP strategy and portfolio management, including patents, trademarks, copyrights, and trade dress. He also provides strategic counsel on data rights, licensing, freedom-to-operate analyses, monetization, dispute resolution, and IP due diligence. Roger focuses on the life sciences sector, assisting clients with research tools, diagnostics, medical devices, analytical software, digital therapeutics, and biomanufacturing platforms.

Roger specializes in emerging technologies, including precision medicine (genomic sequencing, AI/ML, computational genomics, molecular diagnostics, companion diagnostics), digital health solutions (mobile apps, clinical decision support, imaging diagnostics, wearables, software), and 3D printing/bioprinting.

Before joining Norton Rose Fulbright, Roger was Director and IP Counsel at Thermo Fisher Scientific, leading global IP strategy for molecular diagnostics, bioproduction, nucleic acid sequencing, and life sciences tools.


Roger was recognized by Lawdragon in 2005 as one of the "500 Leading Global IP Lawyers." He has been recommended by the Legal 500 for intellectual property in 2019, 2024, and 2025, and was named a leading IP lawyer by IAM Patent 1000 in 2024 and 2025.